In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CureVac AG

www.curevac.com

Latest From CureVac AG

Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State

TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.

Commercial Deals

Tech Transfer Roundup: OncoSec Will Investigate CAR-T In Breast Cancer With Dana-Farber

Building on research by Dana-Farber professor Wayne Marasco, the partners are backing a bispecific approach to CAR-Ts in solid tumors. Seelos licenses a Parkinson’s gene therapy candidate from Duke.

Deals Business Strategies

Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata

Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.

Regenerative Medicine Business Strategies

Interview: BioNTech And Pfizer Explore mRNA Flu Vaccines In $120m+ Deal

The German biotech's CBO and CCO Sean Marett tells Scrip that the Pfizer pact represents the first time BioNTech has moved into infectious disease in humans and could lead to higher potency flu vaccines that could be made more rapidly and cheaply.

Vaccines Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • CureVac GMBH
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • CureVac AG
  • Senior Management
  • Daniel Menichella, PhD, CEO
    Pierre Kemula, PhD, CFO
    Mariola Fotin-Mleczek, PhD, CTO
    Ulrike Gnad-Vogt, MD, CMO
  • Contact Info
  • CureVac AG
    Phone: (49) 7071 9883 0
    Paul-Ehrlich Str. 15
    Tubingen, 72076
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register